New hope for patients with advanced lung cancer

MIAMI – Recent data from the first of a new breed of cancer drug show it outperforming chemotherapy in some cases.

dr Gilberto De Lima Lopes, chief of medical oncology at Sylvester Comprehensive Cancer Center, said the new lung cancer pill targets a specific subset of a genetic mutation called KRAS.

“This is a subset of patients who didn’t have a lot of options that we can give chemotherapy and immunotherapy to, but when those failed they didn’t have a lot of options, but now we can now use this new drug called sotorasib, which specifically blocks KRAS -g12c ​​mutation,” said De Lima Lopes.

He said compared to chemotherapy, the drug helps patients survive without their tumors getting worse and without the side effects of chemotherapy.

The drug, sold under the brand name Lumakras, carries the risk of liver problems.

In other health news, Moderna and Merck announced some achievements in the development of a potential skin cancer vaccine.

The companies said patients taking Merck’s potential vaccine and immunotherapy Keytruda saw a 44 percent reduction in the risk of the cancer dying or coming back.

Keytruda is Merck’s best seller and helps the body to recognize and fight cancer cells.

The companies plan to begin the third phase of the study next year.

They also want to expand their research to other types of tumors.

And a multinational analysis of more than 32 million deaths from cardiovascular disease found more people died on days of extreme temperatures, both hot and cold.

Out of 1,000 cardiovascular deaths, 2.2 additional deaths were associated with extremely hot days and 9.1 with extremely cold days.

Researchers now want policies to be developed to mitigate the effects of extreme temperatures.

Copyright 2022 by WPLG – All rights reserved. New hope for patients with advanced lung cancer

Sarah Y. Kim

InternetCloning is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button